Last updated on November 2016

LixiLan-G EFC13794


Brief description of study

LixiLan-G EFC13794

Detailed Study Description

A 26-week open-label study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP-1 receptor agonist and metformin ± pioglitazone.

Clinical Study Identifier: TX146000

Find a site near you

Start Over

Diabetes Associates Medical Group / Clinical Research

1234 W. Chapman Ave., Suite 106 Orange, CA USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.